Trial Profile
A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2019
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ExFOS
- 22 Apr 2018 Results (country subanalysis) assessing post teriparatide treatment patterns and effectiveness in standard clinical practise in Greek patients presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 22 Apr 2018 Results (n=735) of pooled analysis (subanalysis) of Greek patients from Efos and Exfos studies assessing non-vertebral, clinical vertebral and clinical fracture rates presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 08 Jul 2017 New trial record